Dr. Gerald A. Soff, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 128
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME150688
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 128
- Services billed
- 269
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 30 | 24 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 22 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 17 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 16 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Miami, FL | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 21 payments worth $15,578 in total to this clinician.
| Vertex Pharmaceuticals Incorporated | $9,900 |
|---|---|
| Novartis Pharmaceuticals Corporation | $2,614 |
| Genzyme Corporation | $2,121 |
| Recordati_rare_diseases_inc. | $451 |
| Sobi, Inc | $139 |
| Agios Pharmaceuticals, Inc. | $120 |
| Janssen Biotech, Inc. | $69.51 |
| Beone Medicines USA, Inc. | $60.86 |
| Consulting Fee | $14,865 |
|---|---|
| Food and Beverage | $713 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Oct 8, 2025 | Consulting Fee | $4,200 |
| Vertex Pharmaceuticals Incorporated Jun 25, 2025 | Consulting Fee | $4,200 |
| Novartis Pharmaceuticals Corporation Aug 1, 2025 | Consulting Fee | $2,520 |
| Genzyme Corporation Aug 28, 2025 | Consulting Fee ENJAYMO · Hematology | $2,078 |
| Vertex Pharmaceuticals Incorporated Nov 25, 2025 | Consulting Fee | $1,500 |
| Recordati_rare_diseases_inc. Sep 23, 2025 | Consulting Fee ENJAYMO · HEMATOLOGY | $368 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $94,115 in research payments for these studies, mostly to the institutions running them.
- A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
Regeneron Pharmaceuticals, Inc. · Completed · NCT06299111 - PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Ca…
Amgen Inc. - RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastr…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.